JNJ Earnings Date & History
Johnson & Johnson (NEW YORK STOCK EXCHANGE, INC.) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 6:24 PM ET
Johnson & Johnson
Pharmaceuticals
- Next earnings date
- Tuesday, October 13, 2026
- Reporting session
- Time TBD
- EPS estimate
- $2.95
- Revenue estimate
- $25.57B
JNJ earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, July 15, 2026 | Q2 2026 | $2.87 | $2.90 | +0.9% | $25.31B |
| Tuesday, April 14, 2026 | Q1 2026 | $2.69 | $2.70 | +0.3% | $24.06B |
| Wednesday, January 21, 2026 | Q4 2025 | $2.46 | $2.46 | -0.1% | $24.56B |
| Tuesday, October 14, 2025 | Q3 2025 | $2.78 | $2.80 | +0.5% | $23.99B |
| Wednesday, July 16, 2025 | Q2 2025 | $2.71 | $2.77 | +2.3% | $23.74B |
What the market is watching in JNJ's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next JNJ earnings date?
- Johnson & Johnson is scheduled to report on Tuesday, October 13, 2026 (Time TBD). Dates can change until the company confirms them.
- Does JNJ report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for JNJ?
- Consensus EPS for the upcoming quarter is $2.95, on revenue of $25.57B.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
JNJ earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.